Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 12/20 | 0.62 |
| ▸ | MERTK | Q12866 | 12/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | BMPR1B | O00238 | 3/20 | 0.43 |
| ▸ | BMPR1A | P36894 | 3/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.43 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18615349 | 0.89 | MERTK (0.61) | AXLMERTKPIK3C3PIK3CBBMPR1B | |
| SCHEMBL21779420 | 0.88 | AXL (0.52) | AXLMERTKMAP4K4PIK3CBBMPR1B | |
| SCHEMBL18611763 | 0.81 | AXL (0.66) | AXLMERTKPIK3C3BMPR1BBMPR1A | |
| SCHEMBL18616276 | 0.81 | AXL (0.58) | AXLMERTKPIK3C3PIK3CB | |
| SCHEMBL24838532 | 0.78 | AXL (0.77) | AXLMERTK | |
| SCHEMBL18611756 | 0.78 | MERTK (0.61) | AXLMERTKPIK3C3BMPR1BBMPR1A | |
| SCHEMBL18616309 | 0.78 | AXL (0.50) | AXLMERTKMAP4K4BMPR1BBMPR1A | |
| SCHEMBL18580369 | 0.78 | AXL (1.00) | AXLMERTK | |
| SCHEMBL18611170 | 0.76 | MERTK (0.48) | AXLMERTKPIK3C3PIK3CBBMPR1B | |
| SCHEMBL21779418 | 0.76 | BMPR1B (0.68) | AXLMERTKPIK3C3BMPR1BBMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-3344613-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| WO-2017039331-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | AXL 30/4885MERTK 1/4885MAP4K4 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.